The French National Agency for Medicines and Health Products Safety (ANSM) has reported challenges in the supply of duloxetine, a drug used to treat major depressive episodes, generalized anxiety disorder, and certain types of nerve-related pain. These supply issues are due to production problems, and the shortage mainly affects the 30 mg and 60 mg gastro-resistant capsules. Laboratories involved expect a gradual improvement in availability in pharmacies starting in mid-November 2026. To ensure that patients already using duloxetine can continue their treatment, the ANSM has asked manufacturers to release as many supplies as possible, including using safety stocks. It also urges manufacturers to prioritize supplying pharmacies through wholesale distributors rather than selling directly, to ensure an even distribution across the country. An export ban has been in place since mid-September 2026 to help maintain domestic supplies. In the meantime, the ANSM recommends that doctors limit new prescriptions for duloxetine and consider alternative treatments. For major depression or generalized anxiety, alternatives include selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). For nerve pain related to diabetes, options include gabapentinoids or tricyclic antidepressants. Patients currently taking duloxetine should not stop their medication abruptly. If their medication is unavailable, they are advised to contact their doctor to evaluate whether an alternative treatment is appropriate. Doctors can help find a suitable replacement to ensure continuity of care during the supply shortage.